Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction
Authors
Keywords
-
Journal
JAMA Cardiology
Volume 6, Issue 8, Pages 926
Publisher
American Medical Association (AMA)
Online
2021-05-27
DOI
10.1001/jamacardio.2021.1437
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes
- (2020) Mark C. Petrie et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Cost-effectiveness of dapagliflozin in chronic heart failure: an analysis from the Australian healthcare perspective
- (2020) Feby Savira et al. European Journal of Preventive Cardiology
- SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials
- (2020) Faiez Zannad et al. LANCET
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
- (2019) Emelia J. Benjamin et al. CIRCULATION
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Dapagliflozin on Symptoms, Function and Quality of Life in Patients with Heart Failure and Reduced Ejection Fraction: Results from the DAPA-HF Trial
- (2019) Mikhail N. Kosiborod et al. CIRCULATION
- Patient-Reported Outcomes
- (2019) Paul A. Heidenreich JACC-Heart Failure
- Health-Related Quality of Life in Comorbid Heart Failure With Reduced Ejection Fraction and Diabetes Mellitus
- (2019) Muthiah Vaduganathan et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- A Transparent and Consistent Approach to Assess US Outpatient Drug Costs for Use in Cost-Effectiveness Analyses
- (2018) Joseph Levy et al. VALUE IN HEALTH
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Eighth annual INTERMACS report: Special focus on framing the impact of adverse events
- (2017) James K. Kirklin et al. JOURNAL OF HEART AND LUNG TRANSPLANTATION
- Epidemiology of heart failure with preserved ejection fraction
- (2017) Shannon M. Dunlay et al. Nature Reviews Cardiology
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Unknown
- (2016) EUROPEAN JOURNAL OF HEART FAILURE
- Utility of Patient-Reported Outcome Instruments in Heart Failure
- (2016) Anita A. Kelkar et al. JACC-Heart Failure
- Factors associated with variations in hospital expenditures for acute heart failure in the United States
- (2015) Boback Ziaeian et al. AMERICAN HEART JOURNAL
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Determinants of Utility Based on the EuroQol Five-Dimensional Questionnaire in Patients with Chronic Heart Failure and Their Change Over Time: Results from the Swedish Heart Failure Registry
- (2015) Jenny Berg et al. VALUE IN HEALTH
- Quantifying the utility of taking pills for preventing adverse health outcomes: a cross-sectional survey
- (2015) R. Hutchins et al. BMJ Open
- Patient-Accessible Tool for Shared Decision Making in Cardiovascular Primary Prevention
- (2014) Marianna Fontana et al. CIRCULATION
- ACC/AHA Statement on Cost/Value Methodology in Clinical Practice Guidelines and Performance Measures
- (2014) Jeffrey L. Anderson et al. CIRCULATION
- Clinical effectiveness and cost-effectiveness of second- and third-generation left ventricular assist devices as either bridge to transplant or alternative to transplant for adults eligible for heart transplantation: systematic review and cost-effectiveness model
- (2014) P Sutcliffe et al. HEALTH TECHNOLOGY ASSESSMENT
- Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure
- (2014) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Forecasting the Impact of Heart Failure in the United States
- (2013) Paul A. Heidenreich et al. Circulation-Heart Failure
- Fifth INTERMACS annual report: Risk factor analysis from more than 6,000 mechanical circulatory support patients
- (2013) James K. Kirklin et al. JOURNAL OF HEART AND LUNG TRANSPLANTATION
- In-Hospital Resource Use and Medical Costs in the Last Year of Life by Mode of Death (from the HF-ACTION Randomized Controlled Trial)
- (2012) Shelby D. Reed et al. AMERICAN JOURNAL OF CARDIOLOGY
- Lifetime Costs of Medical Care After Heart Failure Diagnosis
- (2010) Shannon M. Dunlay et al.
- Patient Health Status and Costs in Heart Failure
- (2009) Paul S. Chan et al. CIRCULATION
- Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme
- (2008) M. R. MacDonald et al. EUROPEAN HEART JOURNAL
- A Comparison of Patient and Physician-Rated New York Heart Association Class in a Community-Based Heart Failure Clinic
- (2008) Kevin M. Goode et al. JOURNAL OF CARDIAC FAILURE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started